Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

2.

FDA Approves Hemophilia B Second Gene Therapy.

3.

Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer

4.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

5.

Study finds that AI is better at forecasting the risk of developing cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot